Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation Therapy

Clin Nucl Med. 2024 Apr 1;49(4):e164-e165. doi: 10.1097/RLU.0000000000005084. Epub 2024 Feb 6.

Abstract

A 78-year-old man receiving bicalutamide for prostate cancer was referred for a PSMA PET/CT scan to evaluate his gradually rising prostate-specific antigen level. The PSMA PET/CT revealed gynecomastia with radiotracer uptake in bilateral breast parenchyma, a known but rarely reported effect of bicalutamide monotherapy. This scan also demonstrated metastatic progression of his disease in bone and lymph nodes, and he was started on leuprolide injections. Three months after a decrease in his testosterone level, the radiotracer uptake in his breast tissue had resolved, demonstrating that PSMA-avid bicalutamide-induced gynecomastia is reversible.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Androgen Antagonists / adverse effects
  • Androgens
  • Anilides*
  • Gynecomastia* / chemically induced
  • Gynecomastia* / diagnostic imaging
  • Humans
  • Male
  • Nitriles*
  • Positron Emission Tomography Computed Tomography
  • Prostatic Neoplasms* / complications
  • Prostatic Neoplasms* / drug therapy
  • Tosyl Compounds*

Substances

  • Androgen Antagonists
  • Androgens
  • bicalutamide
  • Anilides
  • Nitriles
  • Tosyl Compounds